Rezolute, Inc. (NASDAQ: RZLT) presented expanded analyses from its Phase 3 sunRIZE study at the Pediatric Endocrine Society (PES) 2026 Annual Meeting on May 1, 2026. The presentation, led by Dr. Diva D. De León‑Crutchlow, highlighted additional continuous glucose monitoring (CGM) outcomes that demonstrate significant and consistent glycemic improvements in ersodetug treatment arms versus placebo across multiple pre‑specified and post‑hoc endpoints.
Continue reading for full analysis...